AU7639598A - Treatment of schizophrenia and psychosis - Google Patents

Treatment of schizophrenia and psychosis

Info

Publication number
AU7639598A
AU7639598A AU76395/98A AU7639598A AU7639598A AU 7639598 A AU7639598 A AU 7639598A AU 76395/98 A AU76395/98 A AU 76395/98A AU 7639598 A AU7639598 A AU 7639598A AU 7639598 A AU7639598 A AU 7639598A
Authority
AU
Australia
Prior art keywords
psychosis
schizophrenia
treatment
diseases
methylpyridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU76395/98A
Other languages
English (en)
Inventor
Arnt Jorn
Frank Sams-Dodd
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Publication of AU7639598A publication Critical patent/AU7639598A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU76395/98A 1997-05-29 1998-05-28 Treatment of schizophrenia and psychosis Abandoned AU7639598A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK62097 1997-05-29
DK620/97 1997-05-29
PCT/DK1998/000220 WO1998053820A1 (en) 1997-05-29 1998-05-28 Treatment of schizophrenia and psychosis

Publications (1)

Publication Number Publication Date
AU7639598A true AU7639598A (en) 1998-12-30

Family

ID=8095640

Family Applications (1)

Application Number Title Priority Date Filing Date
AU76395/98A Abandoned AU7639598A (en) 1997-05-29 1998-05-28 Treatment of schizophrenia and psychosis

Country Status (10)

Country Link
US (1) US6297262B1 (enExample)
EP (1) EP1014974B1 (enExample)
JP (1) JP2002500651A (enExample)
AT (1) ATE273007T1 (enExample)
AU (1) AU7639598A (enExample)
DE (1) DE69825605T2 (enExample)
ES (1) ES2227836T3 (enExample)
PT (1) PT1014974E (enExample)
WO (1) WO1998053820A1 (enExample)
ZA (1) ZA984633B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7091357B2 (en) * 2001-12-26 2006-08-15 University Of Kentucky Research Foundation Chain-modified pyridino-N substituted nicotine compounds for use in the treatment of CNS pathologies
ES2660765T3 (es) 2004-06-21 2018-03-26 The Board Of Trustees Of The Leland Stanford Junior University Genes y rutas expresadas de forma diferencial en trastorno bipolar y/o trastorno depresivo mayor
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
CA2620333A1 (en) * 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
ES2534672T3 (es) 2005-11-12 2015-04-27 The Board Of Trustees Of The Leland Métodos relacionados con FGF2 para diagnosticar y tratar la depresión
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
CA2651862A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
EP2382975A3 (en) 2006-05-09 2012-02-29 Braincells, Inc. Neurogenesis by modulating angiotensin
JP2010502722A (ja) 2006-09-08 2010-01-28 ブレインセルス，インコーポレイティド ４−アシルアミノピリジン誘導体を含む組み合わせ
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
CA2875674A1 (en) 2012-06-05 2013-12-12 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating psychiatric disorders or symptoms thereof using ncam peptide mimetics
WO2017147104A1 (en) * 2016-02-24 2017-08-31 Chase Pharmaceuticals Corporation Muscarinic m2-antagonist combinations
WO2018039159A1 (en) * 2016-08-22 2018-03-01 Chase Pharmaceuticals Corporation Muscarinic m2-antagonist combination

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE845612A (fr) 1976-03-23 1977-02-28 Derives de tetrazole-5-carboxamide et leur preparation
DE3421072A1 (de) 1984-06-06 1985-12-12 Heinrich Mack Nachf., 7918 Illertissen 1,4:3,6-dianhydro-hexit-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
ES2061502T3 (es) 1986-06-27 1994-12-16 Beecham Group Plc Nuevos n-heterociclos biciclicos puenteados.
IL83275A (en) 1986-09-08 1994-02-27 Novo Nordisk As Substituted 1, 2, 4- oxadiazolyl piperidine compounds, their preparation and pharmaceutical compositions containing them
GB8714789D0 (en) * 1987-06-24 1987-07-29 Lundbeck & Co As H Heterocyclic compounds
GB8717446D0 (en) 1987-07-23 1987-08-26 Merck Sharp & Dohme Chemical compounds
US5405853A (en) 1987-09-10 1995-04-11 Merck Sharpe & Dohme Ltd. Thiadiazoles useful in the treatment of senile dementia
US5043345A (en) 1989-02-22 1991-08-27 Novo Nordisk A/S Piperidine compounds and their preparation and use
US5328925A (en) 1989-02-22 1994-07-12 Novo Nordisk A/S Piperidine compounds and their use
US5073560A (en) 1990-07-20 1991-12-17 Fisons Corporation Spiro-isoxazolidine derivatives as cholinergic agents
IE922270A1 (en) 1991-07-26 1993-01-27 Akzo Nv Pyrazole derivatives
US5330994A (en) 1992-03-24 1994-07-19 Warner-Lambert Company Tetrahydropyridine isoxazoline derivatives
DE69332641T2 (de) 1992-08-31 2003-11-27 University Of Florida Research Foundation, Inc. Anabasein derivate zur behandlung von degenerativen erkrankungen des nervensystems
IL106877A (en) 1992-09-10 1998-03-10 Lilly Co Eli Rhodanine derivatives for use as medicaments for the treatment of alzheimer's disease
NZ336597A (en) 1993-08-19 2001-02-23 Novo Nordisk As Use of oxa- or thia-diazole substituted pyridines for treatment of schizophrenia
US5705512A (en) 1994-11-10 1998-01-06 Sibia Neurosciences, Inc. Modulators of acetylcholine receptors
US5585388A (en) 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
US5691365A (en) 1995-07-18 1997-11-25 University Of Kentucky Research Foundation Nicotinic receptor antagonists in the treatment of neuropharmacological disorders
US5756501A (en) 1995-12-13 1998-05-26 American Home Products Corporation Saturated and unsaturated pyridazino 4,5-B! indolizines useful as antidementia agents
US5739119A (en) 1996-11-15 1998-04-14 Galli; Rachel L. Antisense oligonucleotides specific for the muscarinic type 2 acetylcholine receptor MRNA

Also Published As

Publication number Publication date
DE69825605T2 (de) 2005-09-15
EP1014974A1 (en) 2000-07-05
WO1998053820A1 (en) 1998-12-03
ATE273007T1 (de) 2004-08-15
PT1014974E (pt) 2004-12-31
JP2002500651A (ja) 2002-01-08
ZA984633B (en) 1998-12-11
ES2227836T3 (es) 2005-04-01
US6297262B1 (en) 2001-10-02
DE69825605D1 (de) 2004-09-16
EP1014974B1 (en) 2004-08-11

Similar Documents

Publication Publication Date Title
AU7639598A (en) Treatment of schizophrenia and psychosis
AU7404791A (en) Treatment of cataract with 15-keto-prostaglandin compounds
AU5860396A (en) Substituted oxazoles for the treatment of inflammation
NO900439D0 (no) Fremgangsmaate for behandling av uorganisk pulver.
AU698509B2 (en) Compositions for the treatment of rheumatoid-based arthritic diseases
WO1996032003A3 (en) Tetrahydroimidazopyridoindolediones and their use as medicaments
AU7931194A (en) Apparatus for treatment of the oral cavity
NO307091B1 (no) Nye pyrido[3,2-e]pyrazinoner, legemiddel inneholdende samme, samt anvendelse av samme for fremstilling av legemiddel
MX9605023A (es) Compuestos substituidos de imidazolidin-2,4-diona como substancias farmaceuticamente activas.
AU7622000A (en) Compounds for the treatment of viral-mediated diseases
AU5802196A (en) Use of bis-1,2,4-triazoles for the manufacture of a medicament for the treatment of cancers
AU6801694A (en) The treatment of small animals
AU6611396A (en) New oxazolidinone derivatives, processes for the production thereof and pharmaceutical agents containing these compounds
AU5801996A (en) Use of 1,2,4-triazole derivatives for the manufacture of a medicament for the treatment of cancers
AU7728698A (en) Oral formulations for treatment of bacteria-induced diseases of the colon
AU7310896A (en) Use of nitroflavonoids for the treatment of anxiety
AU3187595A (en) Compounds for the treatment of restenosis
AU2806692A (en) Medicament for the treatment of anxiety
AU4712696A (en) The use of heterocyclic compounds
TW330933B (en) Furanoeremophilane and eremophilanolide sesquiterpenes for treatment of diabetes
AU3027692A (en) Compositions for the treatment of mammalian diseases
AU4081393A (en) Medicaments for the treatment of anxiety
AU639322B2 (en) Biochemical treatment with 15-dehydroxy-16-oxoprostaglandin compounds
AU7726796A (en) Use of 3-oxa-d-prostaglandins for the manufacture of a medicament for the treatment of glaucoma
AU5018893A (en) Substituted hydrindanes for the treatment of angiogenesis-dependent diseases

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase